GSK 6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief<br>Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2020 under the Company's<br>2017 Performance Share Plan and subject to an additional vesting<br>period of two years from the normal vesting date | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 11,642.706 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2025-05-06 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Emma Walmsley | |||
| b) | Position/status | Chief<br>Executive Officer | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2020 under the Company's 2017 Performance<br>Share Plan and subject to an additional vesting period of two years<br>from the normal vesting date | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £14.4896<br><br><br>. | 5,473.000 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2025-05-06 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: May<br>08, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |